Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

Key Inclusion Criteria: * Multiple Sclerosis (MS) subjects who have a confirmed diagnosis of relapsing-remitting MS according to McDonald criteria #1-4 and a baseline Expanded Disability Status Scale (EDSS) between 0.0 and 5.0, inclusive, who meet either of the following 2 criteria: * Have experienced at least 1 relapse within the 12 months prior to randomization, with a cranial magnetic resonance imaging (MRI) demonstrating lesion(s) consistent with MS , OR * Show evidence of gadolinium-enhancing lesions of the brain on an MRI performed within the 6 weeks prior to randomization. Key Exclusion Criteria: * Diagnosis of primary progressive, secondary progressive, or progressive relapsing MS * History of malignancy * History of severe allergic or anaphylactic reactions or known drug hypersensitivity * History of abnormal laboratory results based on investigator judgment * History of human immunodeficiency virus (HIV) or other immunodeficient conditions * History of drug or alcohol abuse within the 2 years prior to randomization * An MS relapse that has occurred within the 50 days prior to randomization AND/OR the subject has not stabilized from a previous relapse prior to randomization * Positive screening for active infection with Hepatitis B virus or Hepatitis C virus * Varicella or herpes zoster virus infection or any severe viral infection within 6 weeks before Screening * Exposure to varicella zoster virus within 21 days before Screening. * Abnormal blood tests at Screening: Hemoglobin ≤9.0 g/dL, Platelets ≤100 × 10\^9/L, Lymphocytes ≤1.0 × 10\^9/L, Neutrophils ≤1.5 × 10\^9/L, alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT), aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), or gamma-glutamyl-transferase \>2 times the upper limit of normal (ULN) and serum creatinine \>ULN. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.